158 related articles for article (PubMed ID: 34509358)
1. Relationship Between Dietary Phosphate Intake and Biomarkers of Bone and Mineral Metabolism in Australian Adults With Chronic Kidney Disease.
Conley M; Campbell KL; Hawley CM; Lioufas NM; Elder GJ; Badve SV; Pedagogos E; Milanzi E; Pascoe EM; Valks A; Toussaint ND
J Ren Nutr; 2022 Jan; 32(1):58-67. PubMed ID: 34509358
[TBL] [Abstract][Full Text] [Related]
2. A Randomized Trial on the Effect of Phosphate Reduction on Vascular End Points in CKD (IMPROVE-CKD).
Toussaint ND; Pedagogos E; Lioufas NM; Elder GJ; Pascoe EM; Badve SV; Valks A; Block GA; Boudville N; Cameron JD; Campbell KL; Chen SSM; Faull RJ; Holt SG; Jackson D; Jardine MJ; Johnson DW; Kerr PG; Lau KK; Hooi LS; Narayan O; Perkovic V; Polkinghorne KR; Pollock CA; Reidlinger D; Robison L; Smith ER; Walker RJ; Wang AYM; Hawley CM;
J Am Soc Nephrol; 2020 Nov; 31(11):2653-2666. PubMed ID: 32917784
[TBL] [Abstract][Full Text] [Related]
3. Aortic Calcification and Arterial Stiffness Burden in a Chronic Kidney Disease Cohort with High Cardiovascular Risk: Baseline Characteristics of the Impact of Phosphate Reduction On Vascular End-Points in Chronic Kidney Disease Trial.
Lioufas NM; Pedagogos E; Hawley CM; Pascoe EM; Elder GJ; Badve SV; Valks A; Toussaint ND;
Am J Nephrol; 2020; 51(3):201-215. PubMed ID: 32023606
[TBL] [Abstract][Full Text] [Related]
4. Progression of arterial stiffness is associated with changes in bone mineral markers in advanced CKD.
Krishnasamy R; Tan SJ; Hawley CM; Johnson DW; Stanton T; Lee K; Mudge DW; Campbell S; Elder GJ; Toussaint ND; Isbel NM
BMC Nephrol; 2017 Sep; 18(1):281. PubMed ID: 28870151
[TBL] [Abstract][Full Text] [Related]
5. The Effect of Extended Release Niacin on Markers of Mineral Metabolism in CKD.
Malhotra R; Katz R; Hoofnagle A; Bostom A; Rifkin DE; Mcbride R; Probstfield J; Block G; Ix JH
Clin J Am Soc Nephrol; 2018 Jan; 13(1):36-44. PubMed ID: 29208626
[TBL] [Abstract][Full Text] [Related]
6. Longitudinal Evolution of Markers of Mineral Metabolism in Patients With CKD: The Chronic Renal Insufficiency Cohort (CRIC) Study.
Isakova T; Cai X; Lee J; Mehta R; Zhang X; Yang W; Nessel L; Anderson AH; Lo J; Porter A; Nunes JW; Negrea L; Hamm L; Horwitz E; Chen J; Scialla JJ; de Boer IH; Leonard MB; Feldman HI; Wolf M;
Am J Kidney Dis; 2020 Feb; 75(2):235-244. PubMed ID: 31668375
[TBL] [Abstract][Full Text] [Related]
7. Can we IMPROVE cardiovascular outcomes through phosphate lowering in CKD? Rationale and protocol for the IMpact of Phosphate Reduction On Vascular End-points in Chronic Kidney Disease (IMPROVE-CKD) study.
Lioufas N; Toussaint ND; Pedagogos E; Elder G; Badve SV; Pascoe E; Valks A; Hawley C;
BMJ Open; 2019 Feb; 9(2):e024382. PubMed ID: 30796122
[TBL] [Abstract][Full Text] [Related]
8. Associations between vascular calcification, arterial stiffness and bone mineral density in chronic kidney disease.
Toussaint ND; Lau KK; Strauss BJ; Polkinghorne KR; Kerr PG
Nephrol Dial Transplant; 2008 Feb; 23(2):586-93. PubMed ID: 17933842
[TBL] [Abstract][Full Text] [Related]
9. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
Lorenzo Sellares V; Torregrosa V
Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
[TBL] [Abstract][Full Text] [Related]
10. Deoxycholic Acid, a Metabolite of Circulating Bile Acids, and Coronary Artery Vascular Calcification in CKD.
Jovanovich A; Isakova T; Block G; Stubbs J; Smits G; Chonchol M; Miyazaki M
Am J Kidney Dis; 2018 Jan; 71(1):27-34. PubMed ID: 28801122
[TBL] [Abstract][Full Text] [Related]
11. Associations of dietary phosphorus intake, urinary phosphate excretion, and fibroblast growth factor 23 with vascular stiffness in chronic kidney disease.
Houston J; Smith K; Isakova T; Sowden N; Wolf M; Gutiérrez OM
J Ren Nutr; 2013 Jan; 23(1):12-20. PubMed ID: 22406119
[TBL] [Abstract][Full Text] [Related]
12. Effect of lanthanum carbonate on serum calciprotein particles in patients with stage 3-4 CKD-results from a placebo-controlled randomized trial.
Tiong MK; Smith ER; Pascoe EM; Elder GJ; Lioufas NM; Pedagogos E; Hawley CM; Valks A; Holt SG; Hewitson TD; Toussaint ND
Nephrol Dial Transplant; 2023 Feb; 38(2):344-351. PubMed ID: 35212735
[TBL] [Abstract][Full Text] [Related]
13. Responsiveness of FGF-23 and mineral metabolism to altered dietary phosphate intake in chronic kidney disease (CKD): results of a randomized trial.
Sigrist M; Tang M; Beaulieu M; Espino-Hernandez G; Er L; Djurdjev O; Levin A
Nephrol Dial Transplant; 2013 Jan; 28(1):161-9. PubMed ID: 23024219
[TBL] [Abstract][Full Text] [Related]
14. Fibroblast growth factor-23 is associated with C-reactive protein, serum phosphate and bone mineral density in chronic kidney disease.
Manghat P; Fraser WD; Wierzbicki AS; Fogelman I; Goldsmith DJ; Hampson G
Osteoporos Int; 2010 Nov; 21(11):1853-61. PubMed ID: 20012018
[TBL] [Abstract][Full Text] [Related]
15. Plant protein intake is associated with fibroblast growth factor 23 and serum bicarbonate levels in patients with chronic kidney disease: the Chronic Renal Insufficiency Cohort study.
Scialla JJ; Appel LJ; Wolf M; Yang W; Zhang X; Sozio SM; Miller ER; Bazzano LA; Cuevas M; Glenn MJ; Lustigova E; Kallem RR; Porter AC; Townsend RR; Weir MR; Anderson CA;
J Ren Nutr; 2012 Jul; 22(4):379-388.e1. PubMed ID: 22480598
[TBL] [Abstract][Full Text] [Related]
16. A Comparative Study of Serum Phosphate and Related Parameters in Chronic Kidney Disease between the USA and Japan.
Fujii N; Hamano T; Hsu JY; Imai E; Akizawa T; Nitta K; Watanabe T; Iimuro S; Ohashi Y; Matsuo S; Makino H; Hishida A; Alper AB; Horwitz EJ; Hsu CY; Porter AC; Wolf M; Yang W; Nessel L; Feldman HI
Am J Nephrol; 2022; 53(2-3):226-239. PubMed ID: 35226897
[TBL] [Abstract][Full Text] [Related]
17. Relationship between Fibroblast Growth Factor 23 and Biochemical and Bone Histomorphometric Alterations in a Chronic Kidney Disease Rat Model Undergoing Parathyroidectomy.
Liao HW; Hung PH; Hsiao CY; Liou HH; Lin HS; Huang TH; Jou IM; Tsai KJ
PLoS One; 2015; 10(7):e0133278. PubMed ID: 26186634
[TBL] [Abstract][Full Text] [Related]
18. Effects of phosphate binder therapy on vascular stiffness in early-stage chronic kidney disease.
Seifert ME; de las Fuentes L; Rothstein M; Dietzen DJ; Bierhals AJ; Cheng SC; Ross W; Windus D; Dávila-Román VG; Hruska KA
Am J Nephrol; 2013; 38(2):158-67. PubMed ID: 23941761
[TBL] [Abstract][Full Text] [Related]
19. Association between the intake of plant and animal proteins and the serum fibroblast growth factor-23 level in patients with chronic kidney disease analyzed by the isocaloric substitution model.
Yoshioka M; Kosaki K; Matsui M; Mori S; Nishitani N; Saito C; Yamagata K; Kuro-O M; Maeda S
Endocr J; 2023 Jan; 70(1):31-42. PubMed ID: 36058847
[TBL] [Abstract][Full Text] [Related]
20. Pulse Wave Velocity, Central Haemodynamic Parameters, and Markers of Kidney Function in Children.
Marčun Varda N; Močnik M
Kidney Blood Press Res; 2022; 47(1):43-49. PubMed ID: 34657030
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
